SHANGHAI, Jan. 31,
2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ:
ZCMD) ("Zhongchao" or the "Company"), a platform-based internet
technology company offering services to patients with oncology and
other major diseases, today announced that that Chongqing Xinjiang
Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical"), one of the
China operating entities, of which
the Company consolidates the financial results with through certain
contractual arrangements, obtained the general distribution rights
in Mainland China for anti-influenza drug from Natco Pharma Limited
("Natco"). Natco is a vertically integrated and R&D focused
pharmaceutical company in India.
The first batch of cargo has arrived at the port in Chongqing City, and the drug will be
introduced to the market for domestic treatment and prevention of
Type A and Type B influenza viruses after the inspection and
quarantine.
The anti-influenza drug introduced by Xinjiang Pharmaceutical is
Naiditawei®, commonly known as Oseltamivir Phosphate Capsules (the
"Capsule"). Oseltamivir Phosphate is approved by FDA in
United States for the treatment of
flu (influenza Type A and Type B). The Capsule introduced by
Xinjiang Pharmaceutical will be available in 75mg, 45mg and 30mg
sizes to ensure accurate dosage for patients. The Capsule can be
used by children, teenagers and adults with Type A and Type B
influenza. In addition, the Capsule can be taken with water or
other beverages for easier consumption to improve patient
compliance. The Capsule belongs to Medical Insurance Category B
products in China, which is
covered by medical insurance, and it is one of the national
anti-influenza reserve drugs.
Weiguang Yang, Chairman and Chief
Executive Officer of Zhongchao, commented, "the registration and
listing of foreign drugs in China
is an important means to address the clinical needs of patients.
With the gradual ease of the pandemic prevention and control policy
in China and the superimposed
epidemic of Covid-19 and influenza, the demand for related
therapeutic drugs is huge. We plan to introduce more batches of
oseltamivir phosphate capsules this year. We intend to access the
end retail market through offline retail channel of hospitals,
partner pharmacies and distribution teams, and online channel of
the pharmaceutical 2B2C (to-business & to-consumer) procurement
platform of our Zhixun Internet Hospital. We expect to continue
seeking partnerships with more oversea suppliers for quality and
reliable medicines, and improving our distribution channels to
better and more quickly fulfill the needs of patients in
China."
About Zhongchao Inc.
Zhongchao Inc. is an offshore holding company incorporated in
the Cayman Islands. It conducts
operations in China through the
contractual arrangements between its wholly owned subsidiary and
PRC operating entities. Zhongchao Inc. is a platform-based internet
technology company offering services to patients with oncology and
other major diseases. The PRC operating entities provide online
healthcare information, professional training and educational
services to healthcare professionals under their "MDMOOC" platform
(www.mdmooc.org), offer patient management services in the
professional field of tumor and rare diseases through Zhongxin,
offer internet healthcare services through Zhixun Internet
Hospital, and pharmaceutical services through Xinjiang Medical and
operate an online information platform, Sunshine Health Forums, to
general public. More information about the Company can be found at
its investor relations website at http://izcmd.com.
About NATCO PHARMA LIMITED
NATCO PHARMA LIMITED, founded in Hyderabad, India, in 1981, is a vertically
integrated and R&D focused pharmaceutical company engaged in
developing, manufacturing and marketing of finished dosage
formulations ("FDF") and active pharmaceutical ingredients
("APIs"). Its focus is primarily on niche therapeutic areas and
complex products. The company markets and distributes its products
in over 40 countries. It currently has seven manufacturing plants
and modern R&D laboratories in India, one R&D center, four subsidiaries
in Brazil, Canada, Singapore and New
Zealand, and over 4,000 employees worldwide. More
information can be found at https://www.natcopharma.co.in/.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; economic conditions; the growth
of the professional training and educational services market in
China and the other international
markets the Company plans to serve; reputation and brand; the
impact of competition and pricing; government regulations;
fluctuations in general economic and business conditions in
China and the international
markets the Company plans to serve and assumptions underlying or
related to any of the foregoing and other risks contained in
reports filed by the Company with the SEC, the length and severity
of the recent coronavirus outbreak, including its impacts across
our business and operations. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the SEC, which
are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward–looking statements to
reflect events or circumstances that arise after the date
hereof.
For more information, please contact:
At the Company: Pei Xu, CFO
Email: xupei@mdmooc.org
Phone: +86 21-3220-5987
Investor Relations: Sherry Zheng
Weitian Group LLC
Email: shunyu.zheng@weitian-ir.com
Phone: +1 718-213-7386
View original
content:https://www.prnewswire.com/news-releases/zhongchao-inc-announces-introduction-of-indian-anti-influenza-drugs-to-china-301734097.html
SOURCE Zhongchao Inc.